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Abstract 
Zoledronic acid, a bisphosphonate, has been approved for treatment and prevention of osteo-
porosis. This case describes a 73-year-old woman with primary osteoporosis who developed 
transient hepatotoxicity after zoledronic acid (ZOL) treatment. Three days after ZOL infusion, 
aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamyl-
transferase (GGT) were increased by 9.9, 8.1, and 3.7 times, respectively, compared with pre-
treatment values. Liver protective agents were administered. The aminotransferase returned 
within normal ranges 12 days post-infusion. Currently, the relationship of ZOL and liver 
damage is not quite clear, which cannot be explained by its pharmacokinetics. The aim of this 
case report is to increase the clinician’s awareness of the possible adverse effect on the liver, 
and ZOL should be cautiously administered in patients with liver disease. 
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INTRODUCTION 
Bisphosphonates are widely used for the 
treatment of osteoporosis, Paget’s disease, 
metastatic bone disease, multiple myeloma 
and hypercalcaemia of malignancy. Intra-
venous zoledronic acid (5 mg once yearly) 
have also been approved for the treatment 
of osteoporosis. The overall safety and tol-
erability of bisphosphonate treatment for 
osteoporosis has been very good and any 
serious adverse events related to this thera-
py are rare. Until now, a few cases of hepa-
titis developing several months (Halabe et 
al, 2000; Carrére et al., 2003; Yanik et al., 
2007) or years (Phillips, 2007) after starting 
bisphosphonate therapy and resolving sev-
eral months after discontinuing bisphos-
phonates have been reported. Liver biopsy 
(Halabe et al, 2000; Yanik et al., 2007) re-
vealed lesions suggestive of a drug effect. 
Here we report the case of an aged fe-
male patient with primary osteoporosis who 
developed transient hepatotoxicity after 
zoledronic acid (ZOL) treatment. 
 
Case report 
The primary osteoporosis diagnosis was 
established in a 73-year-old Chinese post-
menopausal woman in December 2011. Her 
bone mineral density: The T score of the 
femoral head was -2.6. The patient had no 
severe back pain or fractures. She had no 
history of any obvious predisposing factors 
or liver diseases. She had no history of 
smoking and drinking alcohol. And she had 
no family history of osteoporosis. Physical 
examination was normal. 
The patient was administered per os 
calcium and cholecalciferol supplements 2 
months before ZOL infusion. The patient 
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was not treated with aceraminophen or oth-
er nonsteroidal anti-inflammatory drugs 
prior to or after ZOL infusion. At the day 
after infusion, she experienced a transient 
flu-like syndrome, self-limited less than 3 
days. Three days after ZOL infusion, C-
reactive protein (CRP) increased to 
7.11 mg/dl (normal range 0-0.8 mg/dl), 
while aspartate aminotransferase (AST), 
alanine aminotransferase (ALT), and gam-
ma-glutamyltransferase (GGT) were in-
creased by 9.9, 8.1, and 3.7 times, respec-
tively, compared with pretreatment values 
(Table 1). The abdominal US revealed only 
hepatic mild homogenous brightness with-
out focal lesion of the liver or biliary ducts. 
Serologic tests for hepatitis B and C viruses 
were normal. Liver protective agents (mag-
nesium isoglycyrrhizinate injection 
(150 mg/d)), polyene phosphatidylcholine 
capsules (456 mg 3/d), reduced glutathione 
for injection (1.2 g/d) were administered. 
The CRP, AST, and ALT returned within 
normal ranges 12 days post-infusion, and 
the GGT returned within normal range 24 
days post-infusion (Table 1). 
 
DISCUSSION 
Intravenous bisphosphonates, used in 
oncology and for the treatment of osteopo-
rosis, have been associated with adverse 
events such as acute phase response, hy-
pocalcaemia and secondary hyperparathy-
roidism, musculoskeletal pain, osteonecro-
sis of the jaw and ocular events. Moreover, 
zoledronic acid has been associated with 
renal toxicity. The flu-like symptoms ob-
served following initial exposure to 
zoledronic acid are associated with eleva-
tions in serum TNF-alpha and IL-6 (Dicu-
onzo et al., 2003). Our data support an in-
flammatory element to this phenomenon in 
aged female, with an elevation in CRP. Up 
to now, there are only a few cases of transi-
ent hepatotoxicity following ZOL infusion 
in human. In this case, indeed, the patient 
remained asymptomatic, while the CRP, 
ALT, AST, and GGT were transiently in-
creased. ALT, AST, and GGT increased 
3 days after ZOL, and other potential caus-
es of hepatotoxicity could be excluded, 
which indicates ZOL as a cause of liver in-
jury. 
 
 
 
Table 1: Treatment scheme and biochemical course of the patient 
Date Treatment ALT 
(U/L) 
AST 
(U/L)
GGT 
(U/L) 
Ca 
(mmol/L)
P 
(mmol/L)
Albumin
(g/dl) 
WBC Neutr(%) CRP 
(mg/dl) 
PTH 
(pg/ml) 
Osteo-
calcin 
(ng/ml)
PINP 
(ng/ml) 
2011-
11-22 
Calcium carbonate 
(1.5 g) and calcidol 
(0.25 μg) po 
17 21 40.8 2.35 1.4 40.8 6.38 0.44 <0.341 16.8 12.69 23.08 
2011-
12-1 
Zoledronic acid 
infusion 5 mg              
2011-
12-4 
magnesium iso-
glycyrrhizinate 
injection (150 mg/d) 
polyene phosphati-
dylcholine capsules 
(456 mg 3/d), re-
duced glutathione 
for injection 
(1.2 g/d) 
169 170 85 2.21 0.9  5.57 0.476 7.11    
2011-
12-8 76 31 138 2.29 1.3  5.85 0.475 1.1    
2011-
12-16 30 25 84      3.3    
2011-
12-28 20 25 53          
 
ALT = alanine aminotransferase, AST = aspartate aminotransferase, GGT = gamma-glutamyltrans-
ferase; po per os; PTH = parathyroid hormone; WBC (N/L) = white blood count (neutrophils %/lympho-
cytes %)  
1,000 mg calcium carbonate provides 400 mg elemental calcium. 
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Biopsy-confirmed hepatotoxicity after 
ZOL was previously shown in rats (Dieterle 
et al., 2007). Polyzos et al. (2011) reported 
that a patient with Paget’s disease of bone 
developed transient hepatotoxicity after 
zoledronic acid (ZOL) treatment, her AST, 
ALT, and GGT were increased by 8.1, 6.7, 
and 6.7 times, respectively one day after 
infusion, and were normalized 7 days post-
treatment. There were no serious adverse 
events due to liver disease reported, and the 
clinical significance of such slight increase 
is probably minor. 
The bisphosphonates are essential in the 
treatment of postmenopausal osteoporosis. 
The positive impact of bisphosphonates on 
the management of millions of patients with 
osteoporosis and other metabolic bone dis-
orders has been enormous. Currently, the 
relationship of ZOL and liver damage is not 
quite clear, which cannot be explained by 
its pharmacokinetics. Idiosyncratic sensitiv-
ity to ZOL or adjuvant excipients were sus-
pected. The aim of this case report is to in-
crease the clinician’s awareness of the pos-
sible adverse effect on the liver, and ZOL 
should be cautiously administered in pa-
tients with liver disease.  
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